In late August, centuries-old pharmaceutical company Pfizer did something new: embraced the blockchain.
In a request to join VitaDAO, a blockchain-based biotech collective that requires cryptocurrency buy-in, Pfizer expressed interest in VitaDAO’s pursuit of drugs that could extend one’s lifespan and wanted to work with the collective as a stakeholder (Pfizer declined to comment for this article).
The decision is likely to pass (so far 100% of the votes are in favor of Pfizer joining the DAO). If so, the pharma company will join VitaDAO in mid-October as a stakeholder and, potentially a future acquirer of any intellectual property that comes out of it.
Search less. Close more.
Grow your revenue with all-in-one prospecting solutions powered by the leader in private-company data.
Pfizer’s interest represents a shift in the decades-old biotech lifecycle, one dominated by public research universities and large pharma giants, both of which work hand-in-hand to create many of the drugs we...
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.
INN caught up with cryptocurrency investment expert Dan Hoover to review the current landscape and where the market may be heading. The cryptocurrency investment marketplace has gone through severa...